ME01262B - OBLIK ZA DOZIRANJE KOJI SADRŽI OKSIKODON l NALOKSON - Google Patents
OBLIK ZA DOZIRANJE KOJI SADRŽI OKSIKODON l NALOKSONInfo
- Publication number
- ME01262B ME01262B MEP-2011-173A MEP17311A ME01262B ME 01262 B ME01262 B ME 01262B ME P17311 A MEP17311 A ME P17311A ME 01262 B ME01262 B ME 01262B
- Authority
- ME
- Montenegro
- Prior art keywords
- side effects
- naloxone
- opiate
- dosage form
- pain
- Prior art date
Links
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title claims abstract 7
- 229960004127 naloxone Drugs 0.000 title claims abstract 7
- 239000002552 dosage form Substances 0.000 title claims abstract 6
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title claims abstract 4
- 229960002085 oxycodone Drugs 0.000 title claims abstract 4
- 230000000694 effects Effects 0.000 claims 10
- 208000004998 Abdominal Pain Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 229940127240 opiate Drugs 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000009278 visceral effect Effects 0.000 claims 4
- 208000002881 Colic Diseases 0.000 claims 3
- 206010010774 Constipation Diseases 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims 2
- 201000007637 bowel dysfunction Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- -1 bitatrate Chemical compound 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003871 intestinal function Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (3)
1. Farmaceutski oblik za doziranje sa usporenim oslobađanjem, koji sadrži 40 mg oksikodona, ili neku njegovu farmaceutski prihvatljivu so, i 20 mg naloksona, ili neku njegovu farmaceutski prihvatljivu so, gde su oksikodon, ili neka njegova farmaceutski prihvatljiva so, i nalokson, ili neka njegova farmaceutski prihvatljiva so, prisutni u masenom odnosu 2:1, za upotrebu u tretmanu umorenog do jakog bola, i sindroma opijatne disfunkcije utrobe koji se dešavaju tokom terapije bola, gde pomenuti sindrom opijatne disfunkcije utrobe predstavljaju konstipacija i neželjena dejstva, gde su pomenuta neželjena dejstva tipična neželjena dejstva izazvana sa naloksonom, a biraju se iz grupe koju čine abdominalni bol, grčevi i dijareja.
2. Farmaceutski oblik za doziranje prema Zahtevu 1, za upotrebu u tretmanu umerenog do jakog bola, i sindroma opijatne disfunkcije utrobe, koja se događa tokom pomenute terapije bola, gde pomenuti sindrom opijatne disfunkcije utrobe predstavljaju konstipacija, i neželjena dejstva, gde su pomenuta neželjena dejstva tipična neželjena dejstva izazvana sa naloksonom, a biraju se iz grupe koju čine abdominalni bol, grčevi i dijareja, a gde pomenutu farmaceutski prihvatljivu so predstavlja hidrohlortd, sulfat, bisulfat, tartrat, nitrat, citrat, bitatrat, fosfat, malat, maleat, hidrobromid, hidrojodid, fumarat ili sukcinat.
3. Farmaceutski oblik za doziranje prema Zahtevu 1 ili 2, za upotrebu u tretmanu umerenog do jakog bola. i sindroma opijatne disfunkcije utrobe, koja se događa tokom pomenute terapije bola, gde pomenuti sindrom opijatne disfunkcije utrobe predstavljaju konstipacija i neželjena dejstva, gde su pomenuta neželjena dejstva tipična neželjena dejstva izazvana sa naloksonom, a s biraju se iz grupe koju čine abdominalni bol, grčevi i dijareja, i gde je ovaj oblik za doziranje formulisan za oralnu primenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05004377A EP1695700A1 (en) | 2005-02-28 | 2005-02-28 | Dosage form containing oxycodone and naloxone |
| PCT/EP2006/060341 WO2006089973A2 (en) | 2005-02-28 | 2006-02-28 | Dosage form containing oxycodone and naloxone |
| EP06708567A EP1855657B1 (en) | 2005-02-28 | 2006-02-28 | Dosage form containing oxycodone and naloxone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01262B true ME01262B (me) | 2013-06-20 |
Family
ID=34933990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-173A ME01262B (me) | 2005-02-28 | 2006-02-28 | OBLIK ZA DOZIRANJE KOJI SADRŽI OKSIKODON l NALOKSON |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20080145429A1 (me) |
| EP (5) | EP1695700A1 (me) |
| JP (2) | JP2008531650A (me) |
| KR (1) | KR20070107805A (me) |
| CN (2) | CN104027297A (me) |
| AT (1) | ATE517611T1 (me) |
| AU (2) | AU2006217870B2 (me) |
| BR (1) | BRPI0607975A2 (me) |
| CA (3) | CA2960011A1 (me) |
| CY (1) | CY1111967T1 (me) |
| DE (2) | DE19167974T1 (me) |
| DK (2) | DK1855657T3 (me) |
| ES (1) | ES2370409T3 (me) |
| FI (1) | FI7750U1 (me) |
| HR (1) | HRP20110775T1 (me) |
| IL (2) | IL185514A0 (me) |
| ME (1) | ME01262B (me) |
| MX (1) | MX2007010494A (me) |
| NZ (1) | NZ588875A (me) |
| PL (1) | PL1855657T3 (me) |
| PT (1) | PT1855657E (me) |
| RS (1) | RS51984B (me) |
| RU (1) | RU2428985C2 (me) |
| SI (1) | SI1855657T1 (me) |
| UA (1) | UA93543C2 (me) |
| WO (1) | WO2006089973A2 (me) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| EP1685839B8 (en) | 1997-12-22 | 2013-06-26 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist |
| CA2446550C (en) | 2001-05-11 | 2012-03-06 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
| US7056500B2 (en) | 2001-10-18 | 2006-06-06 | Nektar Therapeutics Al, Corporation | Polymer conjugates of opioid antagonists |
| ES2627298T3 (es) | 2002-04-05 | 2017-07-27 | Mundipharma Pharmaceuticals S.L. | Preparación farmacéutica que contiene oxicodona y naloxona |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| BRPI0606339A2 (pt) * | 2005-01-28 | 2009-06-16 | Euro Celtique Sa | formas farmacêuticas resistentes a álcool |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
| DE202006018609U1 (de) * | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung |
| BRPI0718554A2 (pt) * | 2006-11-07 | 2013-11-19 | Nektar Therapeutics Al Corp | Formas de dosagem e co-admimstração de um agonista opióide e um antagonista opióide |
| US20090004231A1 (en) | 2007-06-30 | 2009-01-01 | Popp Shane M | Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring |
| EP2042176A1 (en) * | 2007-09-26 | 2009-04-01 | Euro-Celtique S.A. | Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease |
| WO2009076764A1 (en) | 2007-12-17 | 2009-06-25 | Labopharm Inc. | Misuse preventative, controlled release formulation |
| MX2010008138A (es) | 2008-01-25 | 2010-08-10 | Gruenenthal Gmbh | Forma de dosis farmaceutica. |
| TWI524904B (zh) | 2008-05-09 | 2016-03-11 | 歌林達股份有限公司 | 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法 |
| PT2317991T (pt) * | 2008-07-07 | 2017-08-03 | Euro Celtique Sa | Utilização de antagonistas de opióides para tratar a retenção urinária |
| ES2509497T3 (es) | 2008-12-16 | 2014-10-17 | Paladin Labs Inc. | Formulación de liberación controlada para evitar un uso indebido |
| RS58240B1 (sr) * | 2009-03-10 | 2019-03-29 | Euro Celtique Sa | Farmaceutske kombinacije sa trenutnim oslobađanjem koje obuhvataju oksikodon i nalokson |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| EP2456425B1 (en) | 2009-07-22 | 2015-10-21 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opioids |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
| US9993433B2 (en) | 2010-05-10 | 2018-06-12 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| ES2408343B2 (es) * | 2010-05-10 | 2014-07-17 | Euro-Celtique, Sa | Composiciones farmacéuticas que comprenden hidromorfona y naloxona |
| MX344846B (es) | 2010-05-10 | 2017-01-10 | Euro-Celtique S A * | Combinacion de granulos cargados activos con activos adicionales. |
| PE20131101A1 (es) * | 2010-08-13 | 2013-09-23 | Euro Celtique Sa | Formulaciones estables al almacenamiento de oxicodona y naloxona |
| EP2611426B1 (en) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| KR20130137627A (ko) | 2010-09-02 | 2013-12-17 | 그뤼넨탈 게엠베하 | 음이온성 중합체를 포함하는 내변조성 투여형 |
| MY162895A (en) * | 2010-12-28 | 2017-07-31 | Euro Celtique Sa | A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease |
| KR20140053159A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
| CN103857386A (zh) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | 提供药物立即释放的抗破碎片剂 |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| HK1206978A1 (en) | 2012-04-17 | 2016-01-22 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| PT2838512T (pt) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| AU2014273226B2 (en) | 2013-05-29 | 2019-06-27 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
| EP3019157A1 (en) | 2013-07-12 | 2016-05-18 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| WO2015011189A1 (en) | 2013-07-23 | 2015-01-29 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| EP3068397A1 (en) | 2013-11-13 | 2016-09-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| CN106163499A (zh) | 2014-03-14 | 2016-11-23 | 欧皮安特制药有限公司 | 鼻用药物产品及其使用方法 |
| CN106572980A (zh) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | 包含他喷他多的防篡改即释胶囊制剂 |
| MX2016015417A (es) | 2014-05-26 | 2017-02-22 | Gruenenthal Gmbh | Multiparticulas protegidas contra vertido de dosis etanolico. |
| WO2016016431A1 (en) * | 2014-08-01 | 2016-02-04 | Krka, D.D., Novo Mesto | Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| US20160256451A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Dosage of naloxone |
| US20160256453A1 (en) * | 2015-03-06 | 2016-09-08 | Develco Pharma Schweiz Ag | Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen |
| US20160310429A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| WO2016193456A2 (en) * | 2015-06-03 | 2016-12-08 | Develco Pharma Schweiz Ag | Opioid receptor antagonist for use in treating patients with severe constipation |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| AU2018291397A1 (en) | 2017-06-30 | 2020-01-16 | Purdue Pharma L.P. | Method of treatment and dosage forms thereof |
| US12475984B2 (en) * | 2019-08-05 | 2025-11-18 | Rxassurance Corporation | Techniques for providing interactive clinical decision support for drug dosage reduction |
| US20240131022A1 (en) * | 2022-03-11 | 2024-04-25 | John Abernethy | Opioid overdose reversal mixtures |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (me) * | 1960-11-29 | |||
| US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| NL6714885A (me) * | 1967-11-02 | 1969-05-06 | ||
| US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
| FR2183546B1 (me) * | 1972-05-10 | 1975-06-20 | Servier Lab | |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3916889A (en) * | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
| US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
| GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US3966040A (en) * | 1975-03-05 | 1976-06-29 | Hazelwood John E | Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
| US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
| GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| DE3812567A1 (de) * | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
| EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
| IL119660A (en) * | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| DE4325465B4 (de) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Orales pharmazeutisches Präparat für die Schmerztherapie |
| US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
| US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US5865161A (en) * | 1995-01-04 | 1999-02-02 | Bruce; Norman R. | Baseball pitching device |
| US20020006964A1 (en) * | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
| DE19651551C2 (de) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US6207142B1 (en) * | 1997-04-14 | 2001-03-27 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
| EP1009387B1 (en) * | 1997-07-02 | 2006-04-12 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
| CA2314896C (en) * | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
| EP1685839B8 (en) * | 1997-12-22 | 2013-06-26 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist |
| IL138522A0 (en) * | 1998-03-27 | 2001-10-31 | Upjohn Co | Use of cabergoline in the treatment of restless legs syndrome |
| US20030178031A1 (en) * | 1999-05-07 | 2003-09-25 | Du Pen, Inc. | Method for cancer pain treatment |
| WO2000078022A1 (en) * | 1999-06-11 | 2000-12-21 | Telstra New Wave Pty Ltd | A method of developing an interactive system |
| US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| US6258042B1 (en) | 1999-09-17 | 2001-07-10 | James S. Factor | Visual analog scale and method of use for the diagnosis and/or treatment of physical pain |
| GEP20053614B (en) * | 2000-02-08 | 2005-09-26 | Euro Celtique Sa | Compositions for Oral Administration Containing Opioid Agonist |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US7223421B2 (en) * | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
| AR031152A1 (es) * | 2000-10-31 | 2003-09-10 | Upjohn Co | Tratamientos nuevos para el sindrome de piernas inquietas |
| DE60235619D1 (de) * | 2001-04-19 | 2010-04-22 | Warner Lambert Co | Kondensierte bizyklische oder trizyklische aminosäuren |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| CA2446550C (en) * | 2001-05-11 | 2012-03-06 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
| EP1389092B1 (en) * | 2001-05-11 | 2006-11-15 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid dosage form |
| JP4256259B2 (ja) * | 2001-07-18 | 2009-04-22 | ユーロ−セルティーク エス．エイ． | オキシコドン及びナロキソンの医薬配合物 |
| KR20040060917A (ko) * | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
| US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
| PT1414451E (pt) * | 2001-08-06 | 2009-07-31 | Euro Celtique Sa | Formulações agonistas de opióides com antagonista libertável e sequestrado |
| WO2003026676A1 (en) * | 2001-09-24 | 2003-04-03 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
| EP1482835B1 (en) | 2002-03-06 | 2012-09-12 | Euro-Celtique S.A. | Analog scale for measuring pain |
| ES2627298T3 (es) | 2002-04-05 | 2017-07-27 | Mundipharma Pharmaceuticals S.L. | Preparación farmacéutica que contiene oxicodona y naloxona |
| US20030191147A1 (en) * | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
| US7399488B2 (en) * | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| TWI347201B (en) * | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| US7700626B2 (en) * | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
| EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
-
2005
- 2005-02-28 EP EP05004377A patent/EP1695700A1/en not_active Withdrawn
-
2006
- 2006-02-28 AT AT06708567T patent/ATE517611T1/de active
- 2006-02-28 UA UAA200811581A patent/UA93543C2/ru unknown
- 2006-02-28 WO PCT/EP2006/060341 patent/WO2006089973A2/en not_active Ceased
- 2006-02-28 NZ NZ588875A patent/NZ588875A/en unknown
- 2006-02-28 EP EP19167974.5A patent/EP3578173B1/en active Active
- 2006-02-28 EP EP06708567A patent/EP1855657B1/en not_active Revoked
- 2006-02-28 DK DK06708567.0T patent/DK1855657T3/da active
- 2006-02-28 JP JP2007557493A patent/JP2008531650A/ja not_active Withdrawn
- 2006-02-28 BR BRPI0607975-0A patent/BRPI0607975A2/pt not_active Application Discontinuation
- 2006-02-28 PT PT06708567T patent/PT1855657E/pt unknown
- 2006-02-28 SI SI200631121T patent/SI1855657T1/sl unknown
- 2006-02-28 HR HR20110775T patent/HRP20110775T1/hr unknown
- 2006-02-28 CN CN201410239260.4A patent/CN104027297A/zh active Pending
- 2006-02-28 KR KR1020077022380A patent/KR20070107805A/ko not_active Ceased
- 2006-02-28 US US11/885,288 patent/US20080145429A1/en not_active Abandoned
- 2006-02-28 CA CA2960011A patent/CA2960011A1/en not_active Abandoned
- 2006-02-28 EP EP15180143.8A patent/EP2962686B1/en not_active Revoked
- 2006-02-28 MX MX2007010494A patent/MX2007010494A/es active IP Right Grant
- 2006-02-28 RS RS20110458A patent/RS51984B/sr unknown
- 2006-02-28 ES ES06708567T patent/ES2370409T3/es active Active
- 2006-02-28 PL PL06708567T patent/PL1855657T3/pl unknown
- 2006-02-28 AU AU2006217870A patent/AU2006217870B2/en active Active
- 2006-02-28 ME MEP-2011-173A patent/ME01262B/me unknown
- 2006-02-28 CA CA2768075A patent/CA2768075A1/en not_active Abandoned
- 2006-02-28 DE DE19167974.5T patent/DE19167974T1/de active Pending
- 2006-02-28 CN CNA2006800059691A patent/CN101128191A/zh not_active Withdrawn
- 2006-02-28 RU RU2007135991/15A patent/RU2428985C2/ru not_active IP Right Cessation
- 2006-02-28 CA CA2599156A patent/CA2599156C/en active Active
- 2006-02-28 DE DE202006020095U patent/DE202006020095U1/de not_active Expired - Lifetime
- 2006-02-28 EP EP10176716A patent/EP2258353A3/en not_active Withdrawn
-
2007
- 2007-04-13 FI FI20070153U patent/FI7750U1/fi not_active IP Right Cessation
- 2007-08-26 IL IL185514A patent/IL185514A0/en unknown
- 2007-09-27 DK DK200700248U patent/DK200700248U3/da not_active IP Right Cessation
-
2009
- 2009-01-15 IL IL196539A patent/IL196539A0/en unknown
- 2009-03-13 AU AU2009201019A patent/AU2009201019B2/en not_active Ceased
-
2010
- 2010-11-12 US US12/945,164 patent/US20110172259A1/en not_active Abandoned
-
2011
- 2011-10-25 CY CY20111101011T patent/CY1111967T1/el unknown
- 2011-12-16 US US13/329,218 patent/US20120225901A1/en not_active Abandoned
-
2013
- 2013-10-02 US US14/044,175 patent/US20140031382A1/en not_active Abandoned
-
2014
- 2014-04-24 JP JP2014090036A patent/JP6235962B2/ja active Active
-
2017
- 2017-03-23 US US15/467,877 patent/US20180008593A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01262B (me) | OBLIK ZA DOZIRANJE KOJI SADRŽI OKSIKODON l NALOKSON | |
| Reimer et al. | Meeting the challenges of opioid-induced constipation in chronic pain management–a novel approach | |
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| EA200870449A1 (ru) | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами | |
| RU2006140964A (ru) | Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин | |
| WO2001091736A3 (en) | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | |
| WO2006071740A3 (en) | 5ht2c receptor modulator compositions and methods of use | |
| CA2511974A1 (en) | Pharmaceutical compositions comprising fentanyl for intranasal delivery | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| CA2464768A1 (en) | Method and composition for potentiating an opiate analgesic | |
| WO2008144269A3 (en) | Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival | |
| JP2015514743A5 (me) | ||
| HRP20100276T1 (hr) | Gaboksadol za liječenje depresije i drugih afektivnih poremećaja | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| JP2021138703A (ja) | オピオイドとｎ−アシルエタノールアミンの組み合わせ | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| HRP20100373T4 (hr) | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima | |
| MY148084A (en) | Substituted carboxamides as group i metabotropic receptor antagonists | |
| JP2575569B2 (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| JP2019518736A5 (me) | ||
| CN105497019A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| CA2595363A1 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
| CN102711746B (zh) | 用于治疗酒精依赖的药物组合物 | |
| CN102695508A (zh) | 阿片样受体拮抗剂用于胃肠道疾病的用途 |